Tavolixizumab (MEDI 0562) is a humanized monoclonal antibody targeting tumor necrosis factor receptor superfamily member 4 (TNFRSF4, OX40), acting as an OX40 agonist to promote T-cell proliferation and activation, with potent anti-tumor immune potential.
Purity:
95.00%
CAS Number:
[1635395-25-3]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted